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http://dxAbstract: ClinicalTrials.gov is a registry and results database of federally and privately supported
clinical trials conducted worldwide. We sought to answer: what are the characteristics of pain trials;
how frequently are these trials stopped and why; what is the magnitude of attrition due to lack of
efficacy or adverse events; and whether the withdrawal rates depend on pain syndrome. To facilitate
this and subsequent studies, we have developed a system called Sherlock that automatically down-
loads data from ClinicalTrials.gov into a relational database. We included pain interventional trials. To
evaluate attrition, we restricted consideration to prospective randomized, parallel, double-blind, pla-
cebo-controlled trials. Of the 82,867 trials, 6% reported results and 5.6% terminated before the
planned number of subjects was accrued. Of these early terminations, 38% were due to enrollment
difficulties. In the placebo arms, 3.8% of participants withdrew due to lack of efficacy and 4.9% due
to adverse events, with proportions differing among pain conditions. Compared with migraine trials,
in fibromyalgia trials 5.1% more participants withdrew due to lack of efficacy (95% confidence inter-
val [CI], 2.5–7.8%), and 6.4% more withdrew due to adverse events (95% CI, 4.3–8.6%). Nonsteroidal
anti-inflammatory drugs were the treatment class with the lowest adverse events withdrawals. Re-
cruitment challenges account for the largest proportion of noncompleted trials. Attrition rates differ
across pain conditions. Migraine studies had the lowest withdrawal rate. Tools like Sherlock facilitate
conducting research in the ClinicalTrials.gov registry.
Perspective: ClinicalTrials.gov registry enables researchers to get a snapshot of a specific field and
observe changes over time in trial design, including numbers of subjects accrued, and it can inform
clinical trial design. We learned that recruitment challenges account for the largest proportion of
noncompleted trials, attrition rates differed across pain conditions, and migraine studies had the
lowest withdrawal rate.
ª 2013 by the American Pain Society
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linical trials play a critical role in the progression of
medicine and the improvement of humanhealth. A
registry of trials permits researchers and the public
to be aware of the existence of such trials and to act on
the information. Registries of trial protocols promote
awareness of ongoing trials that can facilitate enroll-
ment. Registries of trial results permit evaluation of effi-
cacy and safety of treatment options and can assist in
planning of future trials.August 22, 2012; Revised November 20, 2012; Accepted
r 11, 2012.
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.doi.org/10.1016/j.jpain.2012.12.011In 1997, the US Food and Drug AdministrationModern-
ization Act established a U.S.-based trial registry, and in
2000, the ClinicalTrials.gov registry was launched.5 In
2007, theU.S. FoodandDrugAdministrationAmendments
Act (FDAAA) required the posting of basic results of trials
in ClinicalTrials.gov not later than 1 year after the primary
completion date of the trial. Trials that qualify under
FDAAAA are those trials evaluating a drug, biologic, or
device manufactured in the U.S., conducted under an
investigational new drug application, and those with at
least 1 site in the U.S.11,18 In 2004, the International
Committee of Medical Journal Editors announced that
their journals would only publish the reports of trials
that were registered in a public clinical trial registry
before recruitment started. This decision was an
important motivator for the registration of clinical trials
worldwide.5 ByMay 2012, ClinicalTrials.gov had registered
125,747 trials with locations in 179 countries.17
In the ClinicalTrials.gov registry, trial results are re-
ported in a standard, tabular format and consist of405
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sures and statistical analyses, adverse events informa-
tion, and administrative information. Although not all
studies are required to be registered in the
ClinicalTrials.gov registry and only basic results have to
be reported,16 the breadth of information present in
ClinicalTrials.gov registry has great potential value.
One example of the utility of ClinicalTrials.gov registry
is a study1 that assessed the overall characteristics of all
interventional clinical trials registered in the
ClinicalTrials.gov. The authors challenged the capacity
of clinical trials to supply sufficient high quality evidence
to ensure confidence in treatment guideline recommen-
dations1,15 because of the degree of heterogeneity in
study designs and the small sample sizes of the trials
(ie, 62% enrolled 100 or fewer participants).1,15
Searching for basic information in theClinicalTrials.gov
registry is relatively straightforward. The web interface
provided by the National Library of Medicine permits
the user to find studies based on a wide variety of study
characteristics, including conditions being treated, char-
acteristics of participants, or availability of trial results.
A search in the ClinicalTrials.gov registry returns a list of
studies that meet the specified search criteria, and the
available trial information can be downloaded, but not
in a format ready for quantitative analyses, which is an
obstacle to performing meta-analyses. To address this
limitation, we developed Sherlock, a system that auto-
matically downloads data from ClinicalTrials.gov, parses
and organizes the information, and creates a database
with numeric fields that is ready for statistical analyses.
In this study, we used the Sherlock system to illustrate
the value of the data available in ClinicalTrials.gov for
designing clinical trials for pain treatments. Specifically,
we addressed the following questions: 1) What are the
study design characteristics of pain clinical trials and
have these changed in the last 4 years? 2) How frequently
are pain clinical trials stopped before the planned num-
ber of subjects is accrued andwhy? 3)What is the magni-
tude of attrition due to lack of efficacy or adverse events
in the placebo and active arms of pain trials? and 4) Does
the withdrawal rate depend on pain syndrome or drug
tested?
Methods
The search of ClinicalTrials.govwas conducted through
May 22, 2012, using the Sherlock system.
Sherlock
Sherlock includes all historical data and daily updates
are routinely downloaded from ClinicalTrials.gov in an
XML format. The data are automatically processed and
loaded into a relational database (Microsoft SQL Server
2008 R2; Microsoft Corp, Redmond, WA). Data process-
ing steps include 1) conversion of the XML text repre-
senting numbers into corresponding numeric fields
such as participant flow counts and outcome measure
values; 2) linking between comparison groups and treat-
ment arms; 3) mapping of the studied conditions to
Systematized Nomenclature of Medicine Clinical Terms(SNOMED-CT) and the Medical Dictionary for Regulatory
Activities (MedDRA) terminology using the Unified
Medical Language System (UMLS); 4) mapping of the in-
vestigated interventions to the mechanism of action in-
formation extracted from the Pharmaprojects Pipeline
database, a commercial database, supplied by Citeline;
and 5) manual validation of the mapping algorithms to
ensure accuracy.
The conversion of the XML text into numeric fields is
a straightforward conversion from text to numbers. Link-
ing between comparison groups and treatment arms re-
quired the development of a heuristic algorithm that
performed fuzzy text matching (ie, use of term normaliza-
tion, stringmatching,word counting) in various datafields
such as group title, group description, arm title, arm label,
arm type, and arm intervention. For themapping of condi-
tions to referencevocabularies,wefirstmatchedthecondi-
tions to SNOMED-CT terms extracted from UMLS using
a string-matching algorithm that took into account word
stems, synonyms, and matching word counts. The
condition-SNOMED term association was then used to
identify a corresponding MedDRA term using the linkage
between SNOMED-CT and MedDRA terms provided by
UMLS. To associate amechanism of actionwith the trial in-
terventions, a similar string-matching algorithm was used
tomap the intervention namewith the drug name known
to Pharmaprojects Pipeline database. The manual valida-
tion included random spot-checking by technical and clin-
ical experts.
Sherlock provides a query interface that facilitates trial
search by any database field including condition, inter-
vention, trial design characteristic, and text keywords.
Identified trial information, including results if available,
can be extracted into a data file with a selected set of
fields and organized by study, arm, or a reported end-
point/outcome. The generated data file represents an
analysis-ready data set that can be further investigated
using any statistical software package.Studies Included
We included interventional clinical trials that assessed
pain-related conditions. ClinicalTrials.gov defines inter-
ventional studies as ‘‘studies in human beings in which
individuals are assigned by an investigator based on
a protocol to receive specific interventions. The assign-
ment of the intervention may or may not be random.’’4
To identify all pain-related clinical trials, we conducted
a text search using the term ‘‘pain’’ in the following
data fields: study title, summary, description, outcome ti-
tle, condition, condition Medical Subject Heading
(MeSH) term, arm title, armdescription, and study design
fields such as study eligibility and inclusion criteria. This
search would identify trials that included subjects with
pain or that evaluated pain intensity or pain relief. How-
ever, it will omit trials that, despite enrolling subjects
with painful conditions such as osteoarthritis, did not
have the word ‘‘pain’’ in any of the searched fields. The
algorithmwould also miss studies in which the outcomes
evaluatedwere not related to pain, such as imagery, or in
which the scales used may have assessed pain, such as
Cepeda, Lobanov, and Berlin The Journal of Pain 407Western Ontario and McMaster Universities Arthritis In-
dex (WOMAC), but in which the pain subscale was not
specifically mentioned.
Classification of Trials
Two time periods were considered, ‘‘before 2008’’ and
‘‘2008 and after.’’ The year 2008 was chosen as a cutoff
because it was the year in which it became mandatory
in the U.S. to report study results for trials under the
FDAAA scope.
The various pain conditions reported in the registry
were mapped to the MedDRA high-level terms and then
grouped further. For example, diabetic neuropathy and
postherpetic neuralgia were categorized as neuropathic
pain. Drug interventions were grouped by mechanism of
action extracted from the Pharmaprojects Pipeline data-
base. For medications with more than one mechanism of
action, a clinical judgment was used to select one. Tapen-
tadol, anopioidagonist andanadrenergic transmitter up-
take inhibitor, was classified as an opioid.Analysis
To assess how frequently pain clinical trials stopped be-
fore the planned number of subjects was reached, we
grouped the reasons for stopping provided by the spon-
sor into 14 categories that ranged from difficulty in en-
rollment, administrative problems, and funding
problems, to safety reasons and lack of effect.
To conduct attrition assessments, we restricted the
analysis to randomized parallel, double-blind, placebo-
controlled trials to ensure comparability and permit gen-
eralization of the findings.3 A trial was considered
placebo-controlled if one of the arms was designated
as ‘‘placebo comparator’’ by the sponsor. The designation
of the trial arm type is one of the elements required by
ClinicalTrials.gov for interventional trials. To determine
withdrawal rates, we used the information provided in
the ‘‘Reason not completed’’ field, which is required by
ClinicalTrials.gov. We focused the analysis onwithdrawal
counts reported by the sponsor as due to lack of efficacy
or adverse events.
To calculate the attrition rates in the placebo and ac-
tive arms, the number of subjects whowithdrew because
of lack of efficacy or adverse events were divided by the
total number of participants in each arm and then multi-
plied by 100. These analyses were limited to settings with
at least 10 studies (when analyzing the rates in the pla-
cebo arms) or 10 arms (when analyzing the rates in the
active arms), since more precise and reproducible esti-
mates were expected when at least 10 or more studies
or arms were included.
Results were stratified by pain condition and treat-
ment class. To generate a pooled estimate, we calculated
a weighted average using the DerSimonian-Laird ran-
dom-effects meta-analytic model. The weights in this
model are the inverse of the total of within-study plus
among-study variance estimates. A constant of .5 was
added to allow analyses of studies with no withdrawals
and to calculate approximate standard errors, which is
similar to adding a continuity correction to studies withno events in 1 arm to calculate odds ratios or relative
risk in meta-analysis.
To assess the association between the pain syndrome
and the rate of withdrawals due to adverse events or
lack of efficacy, we used a random-effects meta-regres-
sion model, treating withdrawal rates as a continuous
variable, and 95% confidence intervals (CIs) were calcu-
lated. All analyses were conducted with Stata/SE version
10.1 (StataCorp, College Station, TX).Results
The search of ClinicalTrials.gov produced 11,811 inter-
ventional trials identified using the ‘‘pain’’ keyword
search; 2,944 trials were excluded because they did not
assess pain, or assessed conditions such as heart disease,
coronary disease, myocardial ischemia, cardiomyopathy,
or gastroesophageal reflux disease. A total of 8,867 inter-
ventional studies were included in the reported analysis.
Almost 44% of the trials started before 2008. In both
time periods, 80% of the trials were randomized and al-
most 50% were double blinded. The parallel design was
themost commondesign in both periods. The types of in-
terventions evaluated were also similar in both time pe-
riods. Approximately 6% of the pain interventional
studies evaluated behavioral therapies. In both time
periods, the principal sponsors were university organiza-
tions followed by industry, with university organizations
sponsoring a higher proportion of registered trials in the
last 4 years (see Table 1).
Of the 8,867 studies, 495 trials (5.6%) terminated be-
fore the planned number of subjects was accrued. The
most common reason for termination was difficulty
with enrollment (38% of the stopped trials). Table 2 de-
scribes the reasons for terminating the trials before the
planned number of subjects was accrued.
Around6%ofthetrials (521) reportedresults. In these tri-
als, the median (25th–75th percentiles) number of subjects
per arm was 62 (30–139) and the median number of arms
was 2 (2–3). Around 80% of these trials were randomized
controlled trials (432) and 46.5% (247) had a placebo arm.
In terms of attrition in the placebo arm, about 3.8% of
the participants withdrew because of lack of efficacy
(range, 0–28%), and 4.9% withdrew because of adverse
events (range, 0–50%) (unweighted averages).
Migraine, postoperative pain, rheumatoid arthritis, os-
teoarthritis, neuropathic pain, and fibromyalgia were
the conditions with at least 10 placebo-controlled dou-
ble-blind parallel studies with results. The median
(25th–75th percentiles) duration of follow-up in these
trials was 1 day (.5–1) for migraine, 2 days (1–2) for post-
operative pain, 126 days (49–266) for rheumatoid arthri-
tis, 56 days (28–91) for osteoarthritis, 84 days (45–91) for
neuropathic pain, and 84 days (56–84) for fibromyalgia.
The likelihood of dropping out because of lack of
efficacy in the placebo arms differed among the pain
conditions. Compared with trials that evaluated mi-
graine, the percent of withdrawals due to lack of efficacy
was 5.1% larger in trials evaluating fibromyalgia (95%
CI, 2.5–7.8%) and 5.0% larger in trials evaluating rheu-
matoid arthritis (95% CI, 2.0–7.9%) (see Fig 1).
Table 1. Characteristics of Interventional Pain
Trials
BEFORE
2008
2008 AND
AFTER
Number of trials 3,866 (43.6) 5,001 (56.4)
Number of randomized trials 3,120 (80.7) 4,113 (82.2)
Phase
Phase 1 197 (5.1) 276 (5.5)
Phase 1–2 125 (3.2) 196 (3.9)
Phase 2 802 (20.7) 789 (15.8)
Phase 2–3 129 (3.3) 127 (2.5)
Phase 3 998 (25.8) 927 (18.5)
Phase 4 602 (15.6) 882 (17.6)
Phase ‘‘0’’ or missing 1,013 (26.2) 1,804 (36.1)
Number of arms 2.07 6 1.0 2.15 6 1.0
Studies that include both
genders
3,273 (84.7) 4,208 (84.1)
Studies that include only
women
417 (10.8) 612 (12.2)
Number of subjects enrolled 218.4 6 835.0 168.1 6 606.0
Number of subjects enrolled
in Phase 3 studies
399.4 6 1,341.8 334.1 6 927.8
Masking
Double blinded 1,914 (49.5) 2,460 (49.2)
Single blinded 512 (13.2) 863 (17.2)
Open label 1,248 (32.3) 1,615 (32.3)
Missing 192 (5.0) 63 (1.3)
Type of design
Crossover 302 (7.8) 401 (8.2)
Factorial 93 (2.4) 109 (2.2)
Parallel 2,436 (63.0) 3,475 (69.5)
Single group 755 (19.5) 918 (18.4)
Missing 280 (7.2) 98 (2.0)
Type of intervention
Behavioral 242 (6.3) 239 (4.8)
Biological 50 (1.3) 100 (2.0)
Device 376 (9.7) 505 (10.1)
Drug 2,107 (54.5) 2,295 (45.9)
Procedure 544 (14.1) 713 (14.3)
Other and combination 546 (14.1) 1,147 (22.9)
Type of sponsor
Clinical Research Network 58 (1.5) 56 (1.1)
Government, excluding U.S.
Federal
81 (2.1) 149 (3.0)
Industry 1,396 (36.1) 1,446 (28.9)
National Institutes of Health 252 (6.5) 43 (0.9)
U.S. Federal Agency,
excluding NIH
79 (2.0) 63 (1.3)
University/Organization 1,922 (49.7) 3,104 (62.1)
Missing 78 (2.0) 140 (2.8)
NOTE. Values are no. (%) or mean 6 SD.
Table 2. Reasons for Unplanned Termination of
the Trials
REASON FOR TERMINATION
NUMBER OF
TRIALS (%)
Difficulty with enrollment 188 (38.0)
Principal investigator/logistics/administrative
problems
62 (12.5)
Business decision 46 (9.3)
Safety concerns 42 (8.5)
Lack of efficacy 37 (7.5)
Funding problems 36 (7.3)
Study not pertinent 21 (4.2)
Drug/device availability 15 (3)
Never started 9 (1.8)
No actual reason provided 9 (1.8)
Outcome achieved 7 (1.4)
Interim review/recommendation 6 (1.2)
IRB driven decision 4 (0.8)
Other 13 (2.6)
Total number of trials 495 (100)
Abbreviation: IRB, institutional review board.
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cause of adverse events in the placebo arms differed
among the pain syndromes. Compared with trials that
evaluated migraine, the percent of withdrawals due to
adverse events was 6.4% larger in trials evaluating fibro-
myalgia (95% CI, 4.3–8.6%), 3.8% larger in trials evaluat-
ing neuropathic pain (95% CI, 1.8–5.6%), and 2.7%
larger in trials evaluating osteoarthritis (95% CI, 1.0–4%)
(see Fig 2).
In terms of attrition in the active arms, 2.6% of partic-
ipants in placebo-controlled trials withdrew because oflack of efficacy (range, 0–28%) and 7.3% withdrew
because of adverse events (range, 0–66%) (unweighted
averages).
Nonsteroidal anti-inflammatory drugs (NSAIDs), cal-
cium channel blockers, antidepressants, and opioids
were the treatment classes with at least 10 studies or 10
arms reporting results. Postoperative pain, osteoarthritis,
and migraine were the conditions for which at least 2 of
these treatment classes were assessed. NSAIDs were the
treatment class associated with the fewest dropouts be-
cause of adverse events. The proportion of withdrawals
due to adverse events varied with the pain condition
even within the same treatment class. For example, the
dropout rate was #1% in studies that evaluated NSAIDs
andpostoperative pain, and 4% in studies that evaluated
NSAIDs andmigraine. Similarly, the dropout rate was 3%
in studies that evaluated calcium channel blockers and
postoperative pain versus 11% in studies that evaluated
calcium channel blockers and migraine (see Fig 3).Discussion
This study confirms the value of ClinicalTrials.gov regis-
try as a rich source of clinical trial information.
ClinicalTrials.gov contains information for tens of thou-
sands of clinical trials conducted worldwide during the
past 12 years and provides an opportunity for researchers
toobtain and analyze a snapshot of a specific clinical field,
observe changesover time,and informclinical trial design.
By using the ClinicalTrials.gov registry, we learned that
no substantial changes in the characteristics of study de-
signs in pain studies have occurred in the last decade.
In terms of informing researchers about the design of
new clinical trials, our study shows that around 5% of
the interventional studies in the pain field stopped be-
fore the planned number of subjects was accrued; and
that slow recruitment was the principal reason for stop-
ping. Hence, researchers involved in designing and
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Figure 1. Percent of withdrawals due to lack of efficacy by pain condition in the placebo arms of interventional pain trials.
Cepeda, Lobanov, and Berlin The Journal of Pain 409conducting clinical trials should not underestimate the
challenges in recruiting participants.
On average, 9% of the subjects in the placebo arms
withdrew from the trials because of lack of efficacy or ad-
verse events. This empirical-based estimate will help tria-
lists adjust the sample size estimates accordingly when
the aim of the trial is to include a specific number of sub-
jects completing the study, or to estimate minimum ex-
pected event rates when the event of interest is
a composite outcome that includes dropouts because
of lack of efficacy or adverse events as treatment failures.
Interestingly, the pain condition plays a role in partic-
ipant attrition rates due to adverse events and lack of ef-
ficacy. The difference in attrition rates appears to beMigraine
Postoperative pain
Rheumatoid arthritis
Osteoarthritis
Neuropathic pain
Fibromyalgia
Condition
0.50 (0.
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Figure 2. Percent of withdrawals due to adverse events in the place
dition.more than just a consequence of the duration of
follow-up of the trials. We found that withdrawal rates
were similar in short follow-up studies that assessed mi-
graine (1 day) and longer follow-up studies that assessed
osteoarthritis (months), but different in longer follow-
up studies that evaluated fibromyalgia (months).
Althoughwedid not study placebo response per se, our
findings ondropout rates due to lackof efficacy in thepla-
cebo arm support published research suggesting that pain
condition can influence study results. In previous research,
trials that evaluated human immunodeficiency virus neu-
ropathicpainhadhigherplaceboresponse rates thantrials
that evaluated central pain.2 Studies that evaluated fibro-
myalgia appeared to have lower placebo response rates2757
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of the registry data showed that the withdrawal rate due
to lack of efficacy in the placebo arms of trials studying fi-
bromyalgiawas higher than that in trials that studiedneu-
ropathic pain. These findings seem to support previous
assertions thatfibromyalgia subjects exhibit a lowplacebo
response.We also found that studies evaluatingmigraine
had the lowest withdrawal rate due to lack of efficacy,
which could indicate that subjects with migraine exhibit
a higher placebo response.
The dropout rate because of adverse events in the pla-
cebo arm has been termed the ‘‘nocebo effect.’’ The no-
cebo effect is often overlooked, but it has started to
receive more attention recently.8,10,12 The nocebo rates
found in the present study are similar to those reported
in meta-analyses of randomized trials for the treatment
of symptomatic migraine,12 fibromyalgia, and diabetic
neuropathy.8 In the current study, we assessed the no-
cebo effect in these and several other painful conditions.
Our findings reveal the influence of pain syndromes on
the nocebo effect and highlight the complexities of par-
ticipants’ suggestions and expectations. One might ex-
pect that trials of migraine, which exhibited the lowest
dropout rates because of lack of efficacy (and are there-
fore likely to have the highest placebo response rates),
would also have the highest nocebo effect rates, but it
appears to be not the case for migraine as well as other
pain syndromes. One explanation could be that subjects
who are experiencing pain relief aremore tolerant of the
adverse events. This is a pain research area that will def-
initely benefit fromabetter understanding of the impactof participants’ expectations on health outcomes, which
in turnwill help the design and execution of clinical trials
for pain treatments and inform the communication be-
tween health care providers and patients.
There are some limitations toour study. Thefindings are
based on a nonprobabilistic sample.3 In ClinicalTrials.gov,
to the extent that the results of the trials were posted
solely because of mandatory regulatory requirements,
this may limit the generalizability of the results only to
studies that are highly likely to be registered. However,
since it is mandatory to post results of all trials evaluating
medical products manufactured in the U.S., even nonsig-
nificant results are registered,whichwould reduce poten-
tial for a publication selection bias.5 Research has shown
that a third of protocols registered in ClinicalTrials.gov re-
mained unpublished in peer-reviewed biomedical jour-
nals even 30 months after the trial completion.14 Due to
the relative novelty of the result submission requirement,
the compliancewith themandatory reporting of results is
still low13 and only a relatively small number of pain stud-
ies have results posted in the registry. We overcame this
problem by focusing the analyses to circumstances in
which therewere at least 10 studies or 10 arms evaluating
a treatment class for a given type of condition. However,
this meant that we could not evaluate individual condi-
tions or drugs. Assuming that the number of trial results
registered will continue to increase rapidly, it would be
possible to assess individual treatments or conditions in
the near future.
We developed the Sherlock system to create an
analysis-ready database. We believe that tools such as
Cepeda, Lobanov, and Berlin The Journal of Pain 411Sherlock are essential to facilitate conducting research
based on ClincalTrials.gov data. However, there are also
steps that the National Institutes of Health, the sponsor
of ClinicalTrials.gov, could implement to facilitate easier
analysis of the submitted trial data. Currently, a system
such as Sherlock has to map trial results to the corre-
sponding trial arms. We recommend modifying the re-
sults submission process to ensure that sponsor of the
trial provides the mapping. To facilitate identification
of relevant trials and to enable data analysis, Sherlock
maps conditions and interventions evaluated in the trials
to standardized ontologies and controlled vocabularies
of medical conditions and drug names such as MedDRA
and Pipeline. The ClinicalTrials.gov web page interface
uses similar approaches, but unfortunately this informa-
tion is not included into the download options. We sug-
gest making it available for download. We also suggest
that in addition to providing data in an XML format,
the data would be available as a frequently updated da-
tabase dump. Having data available in an analysis-ready
form will significantly increase the value of the
ClinicalTrials.gov registry, will facilitate data utilization
by a larger number of researchers, and could also encour-
age better compliance with the registration mandate.
There are initiatives that, like Sherlock, promote the
use of clinical trial data to inform and optimize future
clinical trials. One is the Clinical Trials Transformation Ini-
tiative (CTTI), which also relies on data from theClinicalTrials.gov registry. A stated aim of this public-
private partnership initiative6 is to make the acquisition
and analysis of the data from ClinicalTrials.gov more
user-friendly. CTTI has created a downloadable database
of ClinicalTrials.gov data based on an annual snapshot.
Unfortunately, this database does not yet include the re-
sults portion of the ClinicalTrials.gov registry. Another
initiative—ACTTION (Analgesic, Anesthetic, and Addic-
tion Clinical Trial Translations, Innovations, Opportuni-
ties, and Network)—specifically targets the pain field.
Key objectives of this public-private partnership are to
expedite the discovery and development of improved
analgesics and to assess the effect of research methods
on study assay sensitivity and efficiency.7
In summary, our study contributes to a growing body of
research showing the value of data in the registry. We
hope that this study will promote the posting of trial re-
sults and that awidespreaduseof the ClinicalTrials.gov re-
sults database will generate further improvements in the
download capabilities of the registry. We learned that re-
cruitment challenges are the most common cause of trial
termination, attrition rates vary across pain conditions,
and migraine studies have the lowest withdrawal rates.Acknowledgment
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